Deciphex Secures €31M for AI-Powered Pathology Solutions
Deciphex, an Irish medtech innovator, has secured €31 million in Series C funding to address the global shortage of pathology professionals. The investment will enhance its AI-powered digital patho...
4/10/20252 min read
Deciphex Secures €31M to Tackle Global Pathology Shortage with AI-Powered Platforms
Introduction
As healthcare systems worldwide grapple with a growing shortage of pathology professionals, Irish medtech innovator Deciphex is stepping up with a powerful AI-driven solution. The company recently announced a €31 million Series C funding round, aimed at expanding its advanced digital pathology platforms—Diagnexia and Patholytix—and extending its global footprint.
The Crisis: A Global Shortage of Pathologists
Pathologists play a critical role in diagnosing diseases from cancer to infections. However, many healthcare systems are facing a dire shortage of these specialists. According to the Royal College of Pathologists, some regions report vacancy rates of up to 50%, leading to delays in diagnosis and treatment. This bottleneck in the diagnostic pipeline is a major healthcare challenge—one Deciphex aims to solve with AI.
The Solution: Diagnexia & Patholytix
Deciphex’s platforms are designed to streamline and accelerate diagnostic workflows by combining the speed of AI with the expertise of human pathologists.
Diagnexia serves as a digital pathology consultation platform, connecting labs with a global network of over 250 sub-specialist pathologists. It enables fast, remote second opinions, which is especially valuable in underserved areas.
Patholytix is their AI-powered platform that assists in automating routine tasks like image analysis and pattern recognition, freeing up pathologists to focus on complex diagnostics.
These platforms can increase pathology productivity by up to 40%, reduce backlogs, and deliver more consistent results across healthcare systems.
The Funding Round: Fuel for Global Expansion
The €31 million investment will help Deciphex:
Scale globally, with targeted expansions in the U.S., Canada, UK, EU, and Japan
Develop next-gen pathology AI models to enhance diagnostic accuracy and speed
Strengthen partnerships with public health systems like Ireland’s HSE and the UK’s NHS
Deciphex's CEO, Donal O’Shea, emphasized that the funding will help the company address a "major diagnostic bottleneck" in global healthcare and make quality pathology accessible to all.
Industry Implications & Competition
The field of AI in pathology is rapidly gaining momentum. While Deciphex is a rising leader, it faces competition from other players like Paige.AI, PathAI, and Proscia, which are also integrating AI into clinical workflows. However, Deciphex’s combination of remote human expertise and machine learning gives it a unique hybrid model in a mostly software-first landscape.
Cost and Accessibility
Although Deciphex’s services are currently more accessible in developed markets, the company’s expansion plans hint at future availability in emerging markets, including Africa and parts of Asia, where diagnostic services are limited.
Cost structures for Deciphex services vary depending on the contract model—some labs pay per consultation, others on a subscription basis. While no public price list is available yet, the company has expressed interest in scaling in a cost-sensitive, tiered model for global adoption.
Final Thoughts
Deciphex is a prime example of how AI can not only improve healthcare quality but also bridge systemic gaps. With €31 million in new funding and strong momentum, the company is well-positioned to lead the digital pathology transformation—bringing faster, more accurate, and more accessible diagnostics to the world.
Sources:
The Times UK – Deciphex Funding Report
Deciphex Official Website
Interested in how AI is transforming diagnostics? Subscribe to our blog for weekly updates